Pharmacogenetics and coumarin dosing - Recalibrating expectations

New England Journal of Medicine

Volumn 369, Issue 24, 2013, Pages 2273-2275

  Zineh, Issam ^a   Pacanowski, Michael ^a   Woodcock, Janet ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN; CYTOCHROME P450 2C9; WARFARIN;

CLINICAL EFFECTIVENESS; CYP2C9 GENE; DRUG EFFICACY; DRUG SAFETY; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICAL DECISION MAKING; MOLECULAR DYNAMICS; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; VKORC1 GENE;

EID: 84889762983     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1314529     Document Type: Article

References (4)

1. Coumadin (warfarin sodium) (package insert). Princeton, NJ: Bristol-Myers Squibb (http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/009218s107lbl. pdf).
2. Flay BR. Efficacy and effectiveness trials (and other phases of research) in the development of health promotion programs. Prev Med 1986;15:451-74.
3. Glasgow RE, Lichtenstein E, Marcus AC. Why don't we see more translation of health promotion research to practice? Rethinking the efficacy-to- effectiveness transition. Am J Public Health 2003;93:1261-7.
4. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness- implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care 2012;50:217-26.